1239. Hepatitis A Epidemiology in Europe: A Systematic Literature Review of the Last 20 Years

Abstract Background Hepatitis A (HepA) global burden is estimated to be > 100 million new cases/year. HepA vaccine-preventable, but outbreaks still occur in regions with low endemicity such as Europe. Guidelines for vaccination adult risk groups are available European countries, adherence recommendations not systematically documented. Here we review data on infection outcomes, discuss the population order assess adequacy of strategies. Methods systematic search PubMed and Embase was performed from January 2001 April 2021. Relevant ECDC, ProMED, ESCAIDE national public health websites also reviewed. We included articles all languages, covering ages published 11 countries (Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Spain, Sweden, Switzerland United Kingdom [UK]). Studies seroprevalence factors virus (HAV) were excluded. Results Overall, 134 85 grey literature reports our review. In Europe, last 20 years, infections reported ages. Annual hospitalization rates exceeded 50% 8 surveyed during 2016–2019. HAV complications by 28 publications (ps): liver transplantation cases 6 ps ; failures 0%–25% patients 23 hemorrhagic 0%–51% ps. Fatality rates, 12 Denmark, Germany Spain 0.05%–0.26%, mostly adults/older adults. Conclusion recorded despite being consistently reported. Although fatality rate low, morbidity high Considering current epidemiological situation HepA-related costs, authorities should raise awareness adapt or improve compliance recommendations. Adherence existing monitored more closely. Universal may considered, similarly strategy adopted States after widespread ongoing outbreaks. Funding GlaxoSmithKline Biologicals SA Disclosures Anar Andani, BSc, Medical director, GSK group companies: Employee|GSK Stocks/Bonds Eveline Bunge, PhD, My institution received grants payment developing studies Jennifer Eeuwijk, MSc, George Kassianos, MD (Hons), FRCGP, FESC, FBGTHA, FFTM RCPS(Glasg), FBHS, FHEA, FAcadMEd, DRCOG, LRCP (Edin.), LRCS LRCP&S (Glas.), DMedAcup., DMedHypn., DFP, AstraZeneca: Advisor/Consultant|British Global Travel Health Association: President|European Scientific Working Group Influenza (ESWI): Board Member|European Lectures|MSD: Advisor/Consultant|Northern Conference Medicine: Lectures|Novavax: Advisor/Consultant|Pfizer: Advisor/Consultant|RAISE Pan-European Committee Influenza: Chair|Royal College General Practitioners: National Immunisation Lead|Sanofi Vaccines: Advisor/Consultant|Seqirus: Advisor/Consultant|UK Service: Lectures|Valneva: Advisor/Consultant Robert Steffen, MD, Advisor/Consultant|GSK Honoraria.